A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants >/=;18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen (CHONQUER study)
Not Available
III
Davis, Elizabeth
NCT06127407
VICC-DTSAR23242
Promoting Self-Management in Head and Neck Cancer Survivors with Lymphedema and Fibrosis [PROMISE Trial]
Not Available
N/A
Murphy, Barbara
NCT06125743
VICC-EDHAN23569
MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial
Not Available
II
Baljevic, Muhamed
NCT05231629
VICC-ITPCL23014
A Phase 3, Randomized, Open-label, Multi-Center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-Muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy SunRISe-5
Not Available
III
Luckenbaugh, Amy
NCT06211764
VICC-DDURO24103
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel
Not Available
N/A
Jallouk, Andrew
NCT05776160
VICC-XDCTT23452
AssesSing a Biomarker PlatfOrm for STratifying IndeterminaTe Pulmonary Nodules; The SPOT IT Platform Trial
Not Available
N/A
Maldonado, Fabien
NCT06638398
VICC-IDTHO24059
A Randomized Phase II Study of Sotorasib versus Continued Consolidation Durvalumab in Patients with KRAS G12C Mutant Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) with Persistent ctDNA Defined Minimal Residual Disease
Not Available
II
Whitaker, Ryan
NCT06333678
VICC-ITTHO23274
A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)
Not Available
III
Luckenbaugh, Amy
NCT06111235
VICC-DDURO24101
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Nave Adult Patients with Metastatic Uveal Melanoma
Not Available
II/III
Johnson, Douglas
NCT06581406
VICC-DTMEL24090
